Our unique experience provides a unique opportunity
Our scientists have deep knowledge of pancreatic cancer and the proteins that are markers of the disease.
World-class research
Reccan is working to translate research discoveries into in-vitro diagnostics that can change the trajectory of pancreatic cancer.
Simple and cost-effective blood test
We develop an in-vitro multiplexed test for early diagnosis of pancreatic cancer using a small amount of blood. Multiplexed biomarker detection, building upon the ‘sandwich’ ELISA concept, is a testing process with significant advantages.
These include enhanced diagnostic precision, improved efficiency, and reduced cost.
Screening accessible in everyday clinic
We are developing a test accessible to all.
Our technology is built on validated well documented platforms.
We develop a test supported by clinical and health economic evidence required for regulatory approvals.
What do we do?
Reccan develops a breakthrough multiplex immunoassay for the quantitative detection of biomarkers in serum that are associated with the presence of pancreatic cancer. Using a proprietary algorithm, multivariate classifier (risk-calculator), to identify the patients probability of pancreatic cancer will assist healthcare providers with the counseling and care of each patient.
We are changing the trajectory of pancreatic cancer
CLINICAL STUDY PROGRAMME
Get involved
If you are interested in partnering with us on our clinical trials or other joint offerings for your patients, please reach out.
Publications
The founders of Reccan publish manuscripts in a variety of peer-reviewed journals to communicate findings in the area of pancreas research and proteomics.
EXPLORE THE LINKS BELOW
Model-based screening for pancreatic cancer in Sweden. Scandinavian Journal of Gastroenterology, 58:5, 534-541 (2023)Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Clin Transl Oncol 24, 297–304 (2022)Pancreatic cancer – the past, the present, and the future, Scandinavian Journal of Gastroenterology, 57:10, 1169-1177 (2022)Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. Clin Transl Oncol 22, 2170–2174 (2020)Proteomic and genomic profiling of pancreatic cancer. Cell biology and toxicology, 35(4), 333–343 (2019).Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma, Oncotarget 2018 Jan 3;9(11):9789-9807Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment, Oncotarget 2018 Jan 6;9(5):6644-6651.Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy?, Expert Rev Proteomics. 2017 Jun;14(6):469-471.Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma, Br J Surg . 2017 Apr;104(5):600-607.Pancreatic cancer: yesterday, today and tomorrow, Future Oncol. 2016 Aug;12(16):1929-46.